Startseite » Publications

Publications i-target

Original Papers


Doctoral students of i-Target are marked in blueproject leaders in black, associated doctoral students (otherwise funded) in grey.




15. Voigt C*, May P*, Gottschlich A*, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT,  Arendt KAM, Heise C, Rataj F, Janssen KP, Königshofff M, Winter H, Himsl I, Thasler WE, Schnurr M, Rothenfußer S, Endres S and Kobold S.
Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.Proceedings of National Academy Sciences USA 2017; 10.1073
JIF 9.6
* contributed equally to this study


14. Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K.
Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences.
Immunol Rev. 2017; 10.1111
JIF 9.6


13. Wennhold K, Thelen M, Schlößer HA, Haustein N, Reuter S, Garcia-Marquez M, Lechner A, Kobold S, Rataj F, Utermöhlen O, Chakupurakal G, Theurich S, Hallek M, Abken H, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M.
Using antigen-specific B cells to combine antibody and T cell-based cancer immunotherapy.
Cancer Immunol Res. 2017; 101158
JIF 8.2


12. Cadilha B, Dormann K, Rataj F, Endres S and Kobold S.
Enabling T cell recruitment to tumours as a strategy for improving adoptive T cell therapy. 
European Oncology and Hematology 2017; 13: 66-73


11. Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, Subklewe MHopfner KP.
SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Oncotarget 2017; doi:10.18632/oncotarget.14500.
JIF 5.0




10. Groß CJ, Mishra R, Schneider KS, Médard G, Wettmarshausen J, Dittlein DC, Shi H, Gorka O, König PA, Fromm S, Magnani G, Ćiković T, Hartjes L, Smollich J, Robertson AAB, Cooper MA, Schmidt-Supprian M, Schuster M, Schroder K, Broz P, Traidl-Hoffmann C, Beutler B, Kuster B, Ruland J, Schneider S, Perocchi F, Groß O.
K+ efflux-independent NLRP3 inflammasome activation by a small molecule targeting mitochondria.
Immunity 2016; 45:1-13.
JIF 24.1


9. Qorraj M, Bruns H, Böttcher M, Weigand L, Saul D, Mackensen A, Jitschin R, Mougiakakos D.
The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.
Leukemia 2016; doi:10.1038/leu.2016.214.
JIF 12.1


8.Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Rataj F, Janssen KP, Endres S, Anz D, Kobold S.
C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer.
Oncoimmunology 2016; 5:e1105428.
JIF 7.3


7. Roskopf C, Braciak TA, Fenn NC, Kobold S, Fey GH, Hopfner KP, Oduncu FS.
Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.
Oncotarget 2016; 7:22579-22589.
JIF 5.0


6. Wiedemann G, Jacobi SChaloupka M, Hamm S, Strobl S, Baumgartner R,Rothenfusser S, Duewell P, Endres SKobold S.
A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.
Oncoimmunology 2016; 5:e1189051.
JIF 7.3


5. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf C, Wildenhain S, Honegger A, Schubert IA, Schele A, Lämmermann K, Fey GH, Jacob U, Lang P, Hopfner KP, Oduncu FS.
CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B lymphoid cells.
Oncotarget; 7:83392-83408.
JIF 5.0




4. Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C, Endres S.
Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.
The Journal of the National Cancer Institute 2015; 107:364.
JIF 15.2


3. Kobold S*, Grassmann S*, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Duewell P, Zeng Y, Schmollinger J, Schnurr M, Endres S#, Rothenfußer S#.
Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy.
The Journal of the National Cancer Institute 2015; 107: djv146.
JIF 15.2

* contributed equally to this study, # share senior authorship


2. Ernst A, Anders H, Kapfhammer H, Orth M, Hennel R, Seidl K, Winssinger N, Belka C, Unkel S, Lauber K.
HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas.
Cancer Letters 2015; 365:211-222.
JIF 5.0


1. Duewell P, Beller E, Kirchleitner S, Adunka T, Bourhis H, Siveke J, Mayr D, Kobold SEndres SSchnurr M.
Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.
Oncoimmunology 2015; 4: e1029698.
JIF 6.3


B Reviews




6. Bauer C, Kühnemuth B, Düwell P, Ormanns S, Gress T, Schnurr M.
Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
Cancer Letters 2016; 381:259-268.
JIF 6.0




5. Weidenbusch M, Rodler S, Anders HJ.
Interleukin-22 in kidney injury and regeneration.
American Journal of Physiology - Renal Physiologogy 2015; 308:F041-1046.
JIF 3.2


4. Lauber K, Brix N, Ernst A, Hennel R, Krombach J, Anders H, Belka C.
Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity.
Cancer Letters 2015; 15:162-167.
JIF 5.0 


3. Schnurr MDüwell P, Bauer C, Rothenfusser S, Lauber KEndres SKobold S.
Strategies to relieve immunosuppression in pancreatic cancer.
Immunotherapy 2015; 7:363-376.
JIF 2.4


2. Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.
Immunotherapy of tumors – Activated T cells as a new treatment modality.
Deutsches Ärzteblatt International 2015; 112:809-15.
JIF 3.7




1. Kobold S, Wiedemann G, Rothenfusser S, Endres S.
Modes of action of TLR7 agonists in cancer therapy.
Immunotherapy 2014; 6:1085-95.
JIF 2.4